NTCELL for Parkinson’s disease
The Phase I clinical trial is underway and we expect the first patient to be consented into the trial in
the next fortnight.
Following consent, the patient will be monitored for eight weeks to establish baseline data, with the
implant expected to occur during Q3.
If the product is shown to be effective in humans, registration in 2018/2019 via a fast-tracked
development programme should be achievable. However, the development programme is at an early
stage and this target registration date may change, depending on the results of the Phase I and